Should I buy or sell Dyne Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks .

What is Dyne Therapeutics' stock price target for 2024?

7 equities research analysts have issued 12-month target prices for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $37.43 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts .

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the start of the year. Since then, DYN stock has increased by 77.8% and is now trading at $23.65. View the best growth stocks for 2024 here .

Are investors shorting Dyne Therapeutics?

Dyne Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,080,000 shares, an increase of 18.5% from the March 15th total of 6,820,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 16.2% of the shares of the stock are short sold. View Dyne Therapeutics' Short Interest .

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DYN earnings forecast .

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.17.

What ETFs hold Dyne Therapeutics' stock?

ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) . iShares Micro-Cap ETF (IWC) .

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vida Ventures Advisors LLC (0.47%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo , Susanna Gatti High , Venture Fund Xi LP Atlas and Wildon Farwell . View institutional ownership trends .

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free DYN Stock Alerts

$23.65

-1.17 (-4.71%)

(As of 04/18/2024 ET)

Compare

Today's Range: $23.54
▼
$25.29
50-Day Range: $22.41
▼
$29.18
52-Week Range: $6.40
▼
$30.27

Volume: 976,339 shs
Average Volume: 2.04 million shs
Market Capitalization: $2.04 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.43

Get Dyne Therapeutics alerts:

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.14 Rating Score
Upside/Downside: 58.3% Upside
$37.43 Price Target
Short Interest: Bearish
16.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.93
Based on 2 Articles This Week
Insider Trading: Selling Shares
$44.69 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.25) to ($3.14) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

277th out of 919 stocks

Pharmaceutical Preparations Industry

112th out of 410 stocks

4.6

Analyst's Opinion

Consensus Rating
Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Dyne Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
16.19% of the float of Dyne Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Dyne Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Dyne Therapeutics has recently increased by 18.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Dyne Therapeutics does not currently pay a dividend.
Dividend Growth
Dyne Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DYN.

2.7

News and Social Media Coverage

News Sentiment
Dyne Therapeutics has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Dyne Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $44,687,450.00 in company stock.
Percentage Held by Insiders
20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.25) to ($3.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dyne Therapeutics is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dyne Therapeutics is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dyne Therapeutics has a P/B Ratio of 15.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DYN Stock News Headlines

April 16, 2024 | americanbankingnews.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Sees Large Increase in Short Interest

April 8, 2024 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | globenewswire.com

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

March 27, 2024 | globenewswire.com

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

March 26, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)

March 25, 2024 | bizjournals.com

Dyne announces CEO transition, former Biogen exec tapped for top spot

March 25, 2024 | marketwatch.com

Dyne Therapeutics Shares Drop 14% on CEO Joshua Brumm Departure

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | finanznachrichten.de

Dyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO Transition

March 25, 2024 | markets.businessinsider.com

Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm

March 25, 2024 | marketwatch.com

Dyne Therapeutics CEO Joshua Brumm to Exit For Investing Career

March 25, 2024 | globenewswire.com

Dyne Therapeutics Announces CEO Transition

March 20, 2024 | fool.com

Dyne Therapeutics (NASDAQ: DYN)

March 18, 2024 | finance.yahoo.com

DYN Apr 2024 30.000 put

March 16, 2024 | finance.yahoo.com

DYN Apr 2024 22.500 call

March 16, 2024 | ca.finance.yahoo.com

DYN Apr 2024 30.000 call

March 14, 2024 | markets.businessinsider.com

Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge

March 13, 2024 | globenewswire.com

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

March 8, 2024 | markets.businessinsider.com

Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know

March 7, 2024 | investing.com

Dyne Therapeutics stock target raised to $41 by Stifel

March 7, 2024 | investing.com

Dyne Therapeutics stock target raised to $47 on promising data

March 7, 2024 | finance.yahoo.com

Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...

March 6, 2024 | markets.businessinsider.com

Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know

March 6, 2024 | markets.businessinsider.com

Dyne Therapeutics: Strong Buy on Promising Clinical Data and Superior Therapeutic Platform

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Dyne Therapeutics Amidst Promising Drug Data and Strategic Market Positioning

March 5, 2024 | seekingalpha.com

Dyne: H2 2024 Muscle Disease Data Could Boost Value

See More Headlines

Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DYN
Previous Symbol: NYSE:DYN
CUSIP: N/A
CIK: 1818794
Web: www.dyne-tx.com
Phone: 781-786-8230
Fax: 781-786-8866
Employees: 141
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $37.43
High Stock Price Target: $56.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +58.3%
Consensus Rating: Buy
Rating Score (0-4): 3.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-235,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -136.35%
Return on Assets: -103.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.53
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.49 per share
Price / Book: 15.87

Miscellaneous

Outstanding Shares: 86,180,000
Free Float: 68,279,000
Market Cap: $2.04 billion
Optionable: Optionable
Beta: 0.95

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Joshua T. Brumm (Age 46)
CEO, President & Director
Comp: $946.5k
Ms. Susanna Gatti High M.B.A. (Age 56)
Chief Operating Officer
Comp: $655.5k
Dr. Oxana Beskrovnaya Ph.D. (Age 62)
Chief Scientific Officer
Comp: $631.08k
Dr. Romesh Subramanian Ph.D. (Age 59)
Co-Founder & Advisor
Comp: $565.17k
Mr. Richard William Scalzo M.B.A. (Age 37)
Senior VP and Head of Finance & Administration
Mr. John Najim M.B.A.
Chief Technical Officer
Ms. Amy Reilly (Age 50)
Senior VP and Head of Corporate Communications & Investor Relations
Mr. Daniel Wilson (Age 52)
Senior VP & Head of Legal
Ms. Kate Mitchell
VP & Head of Human Resources
Ms. Debra Feldman (Age 53)
Chief Regulatory Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings or view top-rated stocks.
What is Dyne Therapeutics' stock price target for 2024?: 7 equities research analysts have issued 12-month target prices for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $37.43 in the next year. This suggests a possible upside of 58.3% from the stock's current price.
View analysts price targets for DYN or view top-rated stocks among Wall Street analysts.
How have DYN shares performed in 2024?: Dyne Therapeutics' stock was trading at $13.30 at the start of the year. Since then, DYN stock has increased by 77.8% and is now trading at $23.65.
View the best growth stocks for 2024 here.
Are investors shorting Dyne Therapeutics?: Dyne Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,080,000 shares, an increase of 18.5% from the March 15th total of 6,820,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 16.2% of the shares of the stock are short sold.
View Dyne Therapeutics' Short Interest.
When is Dyne Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DYN earnings forecast.
How were Dyne Therapeutics' earnings last quarter?: Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.17.

What ETFs hold Dyne Therapeutics' stock?: ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC).
When did Dyne Therapeutics IPO?: Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.
Who are Dyne Therapeutics' major shareholders?: Dyne Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vida Ventures Advisors LLC (0.47%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends.
How do I buy shares of Dyne Therapeutics?: Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dyne Therapeutics (DYN) Stock Price, News & Analysis

Dyne Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dyne Therapeutics Stock (NASDAQ:DYN)

DYN Stock Price History

DYN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DYN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™